Prevention of Postprandial Hyperglycemia by Ophthalmic Nanoparticles Based on Protamine Zinc Insulin in the Rabbit.
instillation
insulin
nanoparticle
polyacrylic acid
postprandial hyperglycemia
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
12 Mar 2021
12 Mar 2021
Historique:
received:
23
02
2021
revised:
09
03
2021
accepted:
11
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Postprandial hyperglycemia, a so-called blood glucose spike, is associated with enhanced risks of diabetes mellitus (DM) and its complications. In this study, we attempted to design nanoparticles (NPs) of protamine zinc insulin (PZI) by the bead mill method, and prepare ophthalmic formulations based on the PZI-NPs with (nPZI/P) or without polyacrylic acid (nPZI). In addition, we investigated whether the instillation of the newly developed nPZI and nPZI/P can prevent postprandial hyperglycemia in a rabbit model involving the oral glucose tolerance test (OGTT). The particle size of PZI was decreased by the bead mill to a range for both nPZI and nPZI/P of 80-550 nm with no observable aggregation for 6 d. Neither nPZI nor nPZI/P caused any noticeable corneal toxicity. The plasma INS levels in rabbits instilled with nPZI were significantly higher than in rabbits instilled with INS suspensions (commercially available formulations, CA-INS), and the plasma INS levels were further enhanced with the amount of polyacrylic acid in the nPZI/P. In addition, the rapid rise in plasma glucose levels in OGTT-treated rabbits was prevented by a single instillation of nPZI/P, which was significantly more effective at attenuating postprandial hyperglycemia (blood glucose spike) in comparison with nPZI. In conclusion, we designed nPZI/P, and show that a single instillation before OGTT attenuates the rapid enhancement of plasma glucose levels. These findings suggest a better management strategy for the postprandial blood glucose spike, which is an important target of DM therapy.
Identifiants
pubmed: 33809008
pii: pharmaceutics13030375
doi: 10.3390/pharmaceutics13030375
pmc: PMC8000746
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Diabetes Res Clin Pract. 1998 Jul;40 Suppl:S51-5
pubmed: 9740503
Materials (Basel). 2020 Apr 03;13(7):
pubmed: 32260210
Arch Intern Med. 2004 Oct 25;164(19):2090-5
pubmed: 15505121
Int J Nanomedicine. 2019 Feb 18;14:1213-1227
pubmed: 30863055
Diabetes Care. 2002 Oct;25(10):1845-50
pubmed: 12351489
Invest Ophthalmol Vis Sci. 1995 Mar;36(3):614-21
pubmed: 7534282
Toxicology. 2014 May 7;319:53-62
pubmed: 24598350
Diabetes Care. 2011 Oct;34(10):2237-43
pubmed: 21949221
J Pharm Sci. 1995 Nov;84(11):1276-9
pubmed: 8587042
Exp Clin Endocrinol Diabetes. 2013 Apr;121(4):210-3
pubmed: 23512415
Diabetologia. 1999 Aug;42(8):926-31
pubmed: 10491751
J Ocul Pharmacol Ther. 1996 Winter;12(4):515-26
pubmed: 8951688
Int J Pharm. 2004 Jan 9;269(1):1-14
pubmed: 14698571
Diabetes. 2010 Nov;59(11):2697-707
pubmed: 20705776
Pharmaceutics. 2020 Jul 04;12(7):
pubmed: 32635523
Exp Eye Res. 2016 Oct;151:47-53
pubmed: 27423550
J Ocul Pharmacol. 1994 Spring;10(1):101-7
pubmed: 8207318
Biol Pharm Bull. 1995 Jan;18(1):169-71
pubmed: 7735235
J Pharmacol Exp Ther. 1989 Apr;249(1):249-55
pubmed: 2651650
World J Diabetes. 2013 Feb 15;4(1):1-7
pubmed: 23493823
J Ocul Pharmacol Ther. 1995 Winter;11(4):565-73
pubmed: 8574820
Ann Intern Med. 2004 Sep 21;141(6):413-20
pubmed: 15381514
Clin Pharmacokinet. 1997 Oct;33(4):285-301
pubmed: 9342504
Int J Mol Sci. 2020 Sep 25;21(19):
pubmed: 32992931
Diabetes. 2005 Jan;54(1):1-7
pubmed: 15616004
Diabetes Care. 2011 May;34 Suppl 2:S120-7
pubmed: 21525442
Int J Nanomedicine. 2019 Oct 01;14:7921-7931
pubmed: 31632009
Diabetes Care. 1999 Feb;22(2):233-40
pubmed: 10333939
Front Bioeng Biotechnol. 2020 Jul 07;8:764
pubmed: 32733870
J Clin Endocrinol Metab. 2006 Mar;91(3):813-9
pubmed: 16352690